Near‐Infrared Nano‐Optogenetic Activation of Cancer Immunotherapy via Engineered Bacteria
Advanced Materials · 2023-02 · 35 (8)
DOI: 10.1002/adma.202207198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 27.12.2022. Verfasst von Xiaoqiang Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Centre for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, 1037 Lu…. Hauptthemen laut MEDLINE: Neoplasms, Nanoparticles. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Certain anaerobic microbes with the capability to colonize the tumor microenvironment tend to express the heterologous gene in a sustainable manner, which will inevitably compromise the therapeutic efficacy and induce off‐tumor toxicity in vivo. To improve the therapeutic precision and controllability of bacteria‐based therapeutics, Escherichia coli Nissle 1917 (EcN), engineered to sense blue light and release the encoded flagellin B (flaB), is conjugated with lanthanide upconversion nanoparticles (UCNPs) for near‐infrared (NIR) nano‐optogenetic cancer immunotherapy. Upon 808 nm photoirradiation, UCNPs emit at the blue region to photoactivate the EcN for secretion of flaB, which subsequently binds to Toll‐like receptor 5 expressed on the membrane of macrophages for activating immune response via MyD88‐dependent signal pathway. Such synergism leads to significant tumor regression in different tumor models and metastatic tumors with negligible side effects. These studies based on the NIR nano‐optogenetic platform highlight the rational of leveraging the optogenetic tools combined with natural propensity of certain bacteria for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Engineering Research Centre for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, 1037 Luoyu Road, Wuhan, 430074, P. R. China.
- Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, Huazhong University of Science and Technology, 1037 Luoyu Road, Wuhan, 430074, P. R. China.
- Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue, Wuhan, 430022, P. R. China.
ORCID-Profile: Sihan Chen, Yan Zhang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhu, X., Chen, S., Hu, X., Zhao, L., Wang, Y., Huang, J., Chen, J., Qiu, Y., Zhang, X., Wang, M., Yang, X., Zhang, Y., & Zhu, Y. (2023). Near‐Infrared Nano‐Optogenetic Activation of Cancer Immunotherapy via Engineered Bacteria. Advanced Materials, 35(8). https://doi.org/10.1002/adma.202207198
Vancouver
Zhu X, Chen S, Hu X, Zhao L, Wang Y, Huang J, et al. Near‐Infrared Nano‐Optogenetic Activation of Cancer Immunotherapy via Engineered Bacteria. Advanced Materials. 2023;35(8). doi:10.1002/adma.202207198
BibTeX
@article{Zhu2023,
author = {Zhu, Xiaoqiang and Chen, Sihan and Hu, Xiuwen and Zhao, Lijun and Wang, Yiqian and Huang, Jinzhao and Chen, Jiawen and Qiu, Yuzhi and Zhang, Xuefei and Wang, Mengdie and Yang, Xiangliang and Zhang, Yan and Zhu, Yanhong},
title = {Near‐Infrared Nano‐Optogenetic Activation of Cancer Immunotherapy via Engineered Bacteria},
journal = {Advanced Materials},
year = {2023},
volume = {35},
number = {8},
doi = {10.1002/adma.202207198}
}
EUVIMED